News
-
-
-
COMMUNIQUÉ DE PRESSE
Cambridge-Based Biotech SynDevRx Announces Scientific Publication Describing Optimized Drug Conjugate Targeting Tumors Sensitive to Obesity/Metabolic Hormones
SynDevRx, Inc. achieves a significant milestone with the publication of a research paper on its optimized MetAP2 inhibitor, evexomostat/SDX-7320. The polymer conjugation approach led to enhanced drug-like properties and safety profile
